Proteomic Technologies to Develop Biomarkers and Functional Analyses for Bone and Soft Tissue Tumors
- *Corresponding Author:
- Yoshiyuki Suehara
Department of Orthopedic Surgery
Juntendo University School of Medicine Hongo 2-1-1
Bunkyo-ku, Tokyo 113-8421, Japan
E-mail: [email protected]
Received date: September 10, 2013; Accepted date: October 22, 2013; Published date: October 25, 2013
Citation: Suehara Y, Kohsaka S, Kubota D, Mukaihara K, Akaike K, et al. (2013) Proteomic Technologies to Develop Biomarkers and Functional Analyses for Bone and Soft Tissue Tumors. J Proteomics Bioinform S3:001. doi: 10.4172/jpb.S3-001
Copyright: © 2013 Suehara Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Proteomics suggests that global protein expression studies can provide important clues for developing biomarkers and understanding tumor biology that cannot be obtained using other approaches. Proteomic studies, such as gelbased analyses and mass spectrometry-based analyses, have provided protein expression profiles that can be used to develop novel diagnostic and therapeutic biomarkers, allowing for the molecular classification of tumors. Recently, we used proteomic approaches to develop biomarkers for bone and soft tissue tumors and identified novel biomarkers for predicting the prognosis and chemosensitivity of bone and soft tissue tumors. Although the predictive power of these biomarkers has been confirmed in large validation studies, functional analyses of the biomarkers (proteins) remain to be conducted. In this article, we describe our proteomics methodology for identifying biomarkers and our approach to evaluating the functions of the biomarkers (proteins) and provide a few examples of our recent proteomic studies.